NCT07560709No Longer Available不适用
Single-Patient Expanded Access Treatment Protocol for Use of RNA Loaded Lipid Particles (RNA-LPs) in a Patient With Recurrent Osteosarcoma
适应症
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 试验地点
- 1
研究概览
简要总结
Treatment of a patient with recurrent osteosarcoma with personalized pp65/tumor mRNA RNA-LP under an individual patient expanded access protocol.
详细描述
The prognosis for patients with recurrent osteosarcoma and measurable disease is dismal and there are no FDA-approved therapies for this indication. A patient was enrolled on a clinical trial to develop a personalized pp65/tumor mRNA RNA-LP; however, the patient progressed following pp65 RNA-LP and had to be taken off treatment. Because the patient had not yet received personalized pp65/tumor mRNA RNA-LP, the IND sponsor treated the patient under an expanded access, individual patient protocol.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 15 Years 至 17 Years（Child）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Participated in clinical trial
- •Received pp65 RNA-LPs alone and had pp65/tumor mRNA RNA-LP manufactured
- •Progressive disease prior to treatment with pp65/tumor mRNA RNA-LP
排除标准
- •Diagnosis of recurrent OSA is not histopathologically confirmed (i.e. pseudoprogression)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
4 期
The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to receive benefit from study intervention in the Pfizer sponsored lorlatinib ongoing studies that will be closed.Secondary malignant neoplasm of other and unspecified respiratory organs,CTRI/2024/07/071046Pfizer Inc.200
招募中
2 期
A study to assess the long-term safety and clinical activity of mRNA-3927 in participants previously enrolled in the mRNA-3927-P101 studyPropionic Acidemia2022-502911-12-00Moderna Therapeutics Inc.6
招募中
2 期
Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard TherapyBiliary Tract CancerHER2Urothelial CarcinomaNCT07506057Xiujuan Qu20
招募中
4 期
To evaluate how safe and tolerable Entrectinib is for Indian patients with advanced or metastatic solid tumors that have certain genetic changes.Malignant neoplasm of unspecifiedpart of bronchus or lung,CTRI/2024/11/076926Roche Products (India) Pvt. Ltd20
招募中
3 期
A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV TreatmentHIV InfectionsNCT07393659ViiV Healthcare181